Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/21980389http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/21980389http://www.w3.org/2000/01/rdf-schema#comment"

Background

Basal cell carcinoma (BCC) tumors are the most common skin cancer and are highly immunogenic.

Objective

The goal of this study was to assess how immune-cell related gene expression in an initial BCC tumor biopsy was related to the appearance of subsequent BCC tumors.

Materials and methods

Levels of mRNA for CD3ε (a T-cell receptor marker), CD25 (the alpha chain of the interleukin (IL)-2 receptor expressed on activated T-cells and B-cells), CD68 (a marker for monocytes/macrophages), the cell surface glycoprotein intercellular adhesion molecule-1 (ICAM-1), the cytokine interferon-γ (IFN-γ) and the anti-inflammatory cytokine IL-10 were measured in BCC tumor biopsies from 138 patients using real-time PCR.

Results

The median follow-up was 26.6 months, and 61% of subjects were free of new BCCs two years post-initial biopsy. Patients with low CD3ε CD25, CD68, and ICAM-1 mRNA levels had significantly shorter times before new tumors were detected (p = 0.03, p = 0.02, p = 0.003, and p = 0.08, respectively). Furthermore, older age diminished the association of mRNA levels with the appearance of subsequent tumors.

Conclusions

Our results show that levels of CD3ε, CD25, CD68, and ICAM-1 mRNA in BCC biopsies may predict risk for new BCC tumors."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.org/dc/terms/identifier"doi:10.1371/journal.pone.0025160"xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Chen M."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Johnson S.L."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Yang E.V."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Glaser R."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Kiecolt-Glaser J.K."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Andridge R."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Bechtel M.A."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"De Renne L.A."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Di Gregorio M."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Hearne D.W."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Herron J.B."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Jewell S.D."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Lambert D.R."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/author"Shana'ah A.Y."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/date"2011"xsd:gYear
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/name"PLoS One"xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/pages"e25160"xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/title"Tumor site immune markers associated with risk for subsequent basal cell carcinomas."xsd:string
http://purl.uniprot.org/citations/21980389http://purl.uniprot.org/core/volume"6"xsd:string
http://purl.uniprot.org/citations/21980389http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/21980389
http://purl.uniprot.org/citations/21980389http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/21980389
http://purl.uniprot.org/uniprot/#_A2N4P8-mappedCitation-21980389http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/21980389
▶